Colon Cancer - First Subjects Enrolled in Epigenomics sponsored PRESEPT Colorectal - TradingMarkets.com
First Subjects Enrolled in Epigenomics sponsored PRESEPT Colorectal - TradingMarkets.com
Berlin, Germany, and Seattle, WA, USA, June 30, 2008 - Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today
Allergy? Blame it on your jewellry - Deccan Herald
Unexplained skin irritations, rashes have happened to many of us, but still, for a majority, the cause for the breakouts remains a big mystery. Now, a group of researchers have answered the long waited query by holding jewellry as the culprit for the
Laffer Curve - FoxBusiness.com
Close your eyes and imagine it’s 1975. Inflation is high, jobs are scarce and the government decides the best way to stimulate the economy is to raise taxes. Nowadays, that approach doesn’t seem to make much sense, but smart people once believed that
Emerging Data on Targeted Therapies for Colorectal Cancer: An Expert - Medscape News
The use of targeted therapies in the management of colorectal cancer has become standard, first with bevacizumab [1] and subsequently cetuximab [2] demonstrating significant benefit in patients with metastatic disease. At the 2008 annual meeting of